Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784904 | 0.94 | F10 (0.40) | F10PDE10ANPY5RTAS1R3TAS1R1 | |
| SCHEMBL785698 | 0.91 | TAS1R3 (0.44) | F10TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL785404 | 0.91 | TAS1R3 (0.44) | F10TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL784390 | 0.89 | CTSS (0.42) | F10TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL785681 | 0.88 | TAS1R3 (0.42) | F10TAS1R3TAS1R1TAS1R2ROCK2 | |
| SCHEMBL784449 | 0.87 | F10 (0.43) | F10NPY5R | |
| SCHEMBL785292 | 0.85 | F10 (0.39) | F10NPY5RROCK2 | |
| SCHEMBL785238 | 0.85 | JAK2 (0.41) | — | |
| SCHEMBL785127 | 0.85 | F10 (0.38) | F10NPY5RTAS1R3TAS1R1ROCK2 | |
| SCHEMBL784276 | 0.85 | F10 (0.39) | F10NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | F10 524/4885PDE10A 589/4885NPY5R 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.